Travere Therapeutics Stock Total Debt
| TVTX Stock | USD 19.06 0.88 4.84% |
Travere Therapeutics fundamentals help investors to digest information that contributes to Travere Therapeutics' financial success or failures. It also enables traders to predict the movement of Travere Stock. The fundamental analysis module provides a way to measure Travere Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Travere Therapeutics stock.
Total Debt To Capitalization is likely to rise to 0.69 in 2024. Travere | Total Debt |
Travere Therapeutics Company Total Debt Analysis
Travere Therapeutics' Total Debt refers to the amount of long term interest-bearing liabilities that a company carries on its balance sheet. That may include bonds sold to the public, notes written to banks or capital leases. Typically, debt can help a company magnify its earnings, but the burden of interest and principal payments will eventually prevent the firm from borrow excessively.
Current Travere Therapeutics Total Debt | 404.78 M |
Most of Travere Therapeutics' fundamental indicators, such as Total Debt, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Travere Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Travere Total Debt Driver Correlations
Understanding the fundamental principles of building solid financial models for Travere Therapeutics is extremely important. It helps to project a fair market value of Travere Stock properly, considering its historical fundamentals such as Total Debt. Since Travere Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Travere Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Travere Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Travere Total Debt Historical Pattern
Today, most investors in Travere Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Travere Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's total debt growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Travere Therapeutics total debt as a starting point in their analysis.
Travere Therapeutics Total Debt |
| Timeline |
In most industries, total debt may also include the current portion of long-term debt. Since debt terms vary widely from one company to another, simply comparing outstanding debt obligations between different companies may not be adequate. It is usually meant to compare total debt amounts between companies that operate within the same sector.
| Competition |
Travere Short Long Term Debt Total
Short Long Term Debt Total |
|
Based on the latest financial disclosure, Travere Therapeutics has a Total Debt of 404.78 M. This is 85.29% lower than that of the Biotechnology sector and 24.63% higher than that of the Health Care industry. The total debt for all United States stocks is 92.39% higher than that of the company.
Travere Total Debt Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Travere Therapeutics' direct or indirect competition against its Total Debt to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Travere Therapeutics could also be used in its relative valuation, which is a method of valuing Travere Therapeutics by comparing valuation metrics of similar companies.Travere Therapeutics is currently under evaluation in total debt category among its peers.
Travere Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Travere Therapeutics from analyzing Travere Therapeutics' financial statements. These drivers represent accounts that assess Travere Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Travere Therapeutics' important valuation drivers and their relationship over time.
| 2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
| Market Cap | 601.2M | 1.3B | 1.9B | 1.3B | 667.7M | 572.6M | |
| Enterprise Value | 743.7M | 1.4B | 2.0B | 1.7B | 1.0B | 646.3M |
Travere Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Travere Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Travere Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Travere Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Travere Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Travere Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Travere Therapeutics' value.| Shares | D. E. Shaw & Co Lp | 2024-09-30 | 1.8 M | Finepoint Capital Lp | 2024-06-30 | 1.8 M | Geode Capital Management, Llc | 2024-09-30 | 1.7 M | Jacobs Levy Equity Management, Inc. | 2024-09-30 | 1.6 M | Assenagon Asset Management Sa | 2024-09-30 | 1.4 M | Kynam Capital Management, Lp | 2024-09-30 | 1.4 M | Balyasny Asset Management Llc | 2024-09-30 | 1.3 M | Woodline Partners Lp | 2024-06-30 | 1.3 M | Emerald Mutual Fund Advisers Trust | 2024-09-30 | 1.2 M | Armistice Capital, Llc | 2024-09-30 | 7.6 M | Blackrock Inc | 2024-06-30 | 7.6 M |
Travere Fundamentals
| Return On Equity | -2.8 | ||||
| Return On Asset | -0.26 | ||||
| Profit Margin | (1.73) % | ||||
| Operating Margin | (0.89) % | ||||
| Current Valuation | 1.71 B | ||||
| Shares Outstanding | 87.03 M | ||||
| Shares Owned By Insiders | 0.65 % | ||||
| Shares Owned By Institutions | 98.59 % | ||||
| Number Of Shares Shorted | 7.99 M | ||||
| Price To Book | 76.10 X | ||||
| Price To Sales | 7.78 X | ||||
| Revenue | 145.24 M | ||||
| Gross Profit | (31.35 M) | ||||
| EBITDA | (326.25 M) | ||||
| Net Income | (376.33 M) | ||||
| Cash And Equivalents | 553.17 M | ||||
| Cash Per Share | 8.65 X | ||||
| Total Debt | 404.78 M | ||||
| Debt To Equity | 2.60 % | ||||
| Current Ratio | 4.71 X | ||||
| Book Value Per Share | (0.39) X | ||||
| Cash Flow From Operations | (280.02 M) | ||||
| Short Ratio | 3.92 X | ||||
| Earnings Per Share | (4.52) X | ||||
| Price To Earnings To Growth | (0.02) X | ||||
| Target Price | 26.94 | ||||
| Number Of Employees | 380 | ||||
| Beta | 0.7 | ||||
| Market Capitalization | 1.58 B | ||||
| Total Asset | 788.91 M | ||||
| Retained Earnings | (1.13 B) | ||||
| Working Capital | 438.87 M | ||||
| Net Asset | 788.91 M |
About Travere Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Travere Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Travere Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Travere Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Travere Stock Analysis
When running Travere Therapeutics' price analysis, check to measure Travere Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Travere Therapeutics is operating at the current time. Most of Travere Therapeutics' value examination focuses on studying past and present price action to predict the probability of Travere Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Travere Therapeutics' price. Additionally, you may evaluate how the addition of Travere Therapeutics to your portfolios can decrease your overall portfolio volatility.